Triple-Action Therapy: Combining Machine Learning, Docking, and Dynamics to Combat BRCA1-Mutated Breast Cancer

Area of Science:

• Biochemistry
• Computational Biology
• Oncology

Background:

• Breast cancer remains a leading cause of mortality in women, with BRCA1 gene mutations significantly increasing risk.
• Current treatments for BRCA1-mutated breast cancer face limitations, including a lack of specific inhibitors and undesirable side effects.
• There is a critical need for advanced therapeutic strategies to effectively manage BRCA1-mutated breast cancer.

Purpose of the Study:

• To identify novel therapeutic agents for BRCA1-mutated breast cancer.
• To overcome the limitations and side effects associated with existing breast cancer treatments.
• To explore the potential of beta-amyrin and narirutin as inhibitors of BRCA1.

Main Methods:

• Utilized machine learning models for high-throughput screening of potential inhibitors.
• Performed molecular docking simulations to assess binding affinity with BRCA1 and its mutated forms.
• Conducted molecular dynamics simulations, principal component analysis (PCA), and free energy landscape (FEL) to evaluate complex stability and binding.

Main Results:

• Identified beta-amyrin and narirutin as promising drug candidates based on molecular docking and RF score calculations.
• Molecular dynamics simulations confirmed the stable binding of beta-amyrin and narirutin to BRCA1, indicated by low RMSD and RMSF values.
• PCA and FEL analyses further supported the favorable and compact binding of these compounds to BRCA1.

Conclusions:

• Beta-amyrin and narirutin demonstrate significant potential as therapeutic agents for BRCA1-mutated breast cancer.
• These compounds offer a promising avenue for developing new treatments with potentially fewer side effects.
• Further research into beta-amyrin and narirutin could lead to advanced therapeutic options for breast cancer patients with BRCA1 mutations.